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Colorectal cancer is one of the most common cancers worldwide, and is influenced by the
interplay of various factors, including a very strong genetic component. For instance, incor-
rect mitochondrial biogenesis is correlated with increased risk of developing colorectal can-
cer. Thus, it is important to understand the consequences of changes in both the expression
and the correct function of the transcription factors that regulate mitochondrial biogenesis,
namely NRF2.
Objectives
The main objective of this paper is to characterise the relationship between NRF2 and colo-
rectal cancer by compiling data from an exhaustive literature search.
Methods
Information was obtained by defining specific search terms and searching in several
databases. After a strict selection procedure, data were tabulated and the relationships
between articles were assessed by measuring heterogeneity and by constructing concep-
tual maps.
Results and discussion
We found a general consensus in the literature that the presence of oxidizing agents as well
as the inhibition of the NRF2 repressor Keap1 maintain NRF2 expression at basal levels.
This predominantly exerts a cytoprotective effect on cells and decreases risk of colorectal
cancer. However, if NRF2 is inhibited, protection against external agents disappears and
risk of colorectal cancer increases. Interestingly, colorectal cancer risk is also increased
when NRF2 becomes overexpressed. In this case, the increased risk arises from NRF2-
induced inflammation and resistance to chemotherapy.
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Conclusion
The proper basal function of NRF2 and Keap1 are essential for preventing oncogenic pro-
cesses in the colon. Consequently, any disruption to the expression of these genes can pro-
mote the genesis and progression of colon cancer.
Introduction
Colorectal cancer (CRC) is one of the most common cancers worldwide, and causes more
than half a million deaths per year [1]. This type of cancer is a useful model for studying both
carcinogenesis and tumour progression, as colonocytes follow a systematic process of prolifer-
ation, differentiation and transformation (adenoma to a carcinoma) [2]. CRC arises from stem
cells in the colon [3], and its development is partly due to functional changes in the mitochon-
drial genome (mtDNA) [4].
Mitochondria play a crucial role in physiological processes, and their deregulation contrib-
utes to the genesis and progression of CRC. This is known as the Warburg effect, which con-
sists of metabolic reprogramming that is characteristic of tumour processes. Thus, it is
important that all genes involved in mitochondrial biogenesis are expressed according to a
standard pattern. This process is highly coordinated and depends on the activity of several key
proteins, including Nuclear Respiratory Factor 1 (NRF1) and Nuclear Respiratory Factor 2
(NRF2), which regulate the expression of respiratory chain proteins, and act as anti-oxidants
[5].
NRF transcription factors control the functionality of the respiratory chain, the main path-
way responsible for producing reactive oxygen species (ROS). ROS are extremely harmful for
cellular micromolecules because they induce tumorigenesis through non-specific reactions
with nucleic acids, proteins, and lipids [6].
NRF2 is considered to be a main defence mechanism and regulator of cell survival [7].
Under healthy conditions, NRF2 protects against tumorigenesis and cancer progression by
attenuating genotoxic compounds that emerge both intrinsically and extrinsically. However,
activation of the NRF2 defence response can promote the survival of both normal and cancer
cells by creating an optimal environment for cell growth. Furthermore, NRF2 protects tumour
cells from oxidative stress, chemotherapeutic agents, and radiotherapy, promoting tumour
genesis and progression, and also metabolic reprogramming to anabolic pathways [8]. Fig 1
shows a simplified diagram of the mechanisms that can activate the transcription factor NRF2.
NRF2 is sequestered by the inhibitor Keap1 and is transcriptionally inactive until Keap1 is dis-
sociated by ROS. This dissociation allows NRF2 to form transcriptionally active complexes
with other proteins, such as Mafs, and, after the transcription of cytoprotective and antioxida-
tive genes, to remove ROS [9].
In this study, we provide a qualitative systematic review to summarize the role of the NRF2




Literature searches and quality assessment were performed according to ’Guidance on the
Conduct of Narrative Synthesis in Systematic Reviews’ (S1 File) [10]. The search results were
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independently assessed by two individuals to minimize bias (one was an expert on this topic
and the other had no knowledge of it).
Design of search strategies and use of Boolean operators
For each search, synonyms, related terms and spelling variations were taken into account, and
Boolean operators were used to relate the terms. Searches were performed on eight different
databases (PubMed, Scopus, Web of Science (WOS), Cochrane library, PysCinfo, PLoS One,
Scielo and PubMedCentral (PMC)) using the following terms:
’Colorectal OR Colon OR Rectum OR Rectal’ AND ’Cancer OR Carcinoma OR Tumor OR
Tumour OR Neoplasm OR Cancer Cells’ AND ’Mitochondrial Biogenesis OR Mitochon-
drial dysfunction OR Mitochondria OR Mitochondrion’ AND ’NRF2 OR NFE2L2 OR
Nuclear Respiratory Factor 2 OR Nuclear Factor Erythroid 2 Like 2’.
’Colorectal OR Colon OR Rectum OR Rectal’ AND ’Cancer OR Carcinoma OR Tumor OR
Tumour OR Neoplasm OR Cancer Cells’ AND ’Warburg effect’ AND ’NRF2 OR NFE2L2
OR Nuclear Respiratory Factor 2 OR Nuclear Factor Erythroid 2 Like 2’.
’Colorectal OR Colon OR Rectum OR Rectal’ AND ’Cancer OR Carcinoma OR Tumor OR
Tumour OR Neoplasm OR Cancer Cells’ AND ’Oxidative phosphorylation OR OXPHOS
OR Anaerobic glycolysis’ AND ’NRF2 OR NFE2L2 OR Nuclear Respiratory Factor 2 OR
Nuclear Factor Erythroid 2 Like 2’.
To retrieve optimal results when using the Scopus database, it was necessary to modify the
search criteria. Thus, only the following more specific terms were used:
’CRC’ AND ’NRF2 OR NFE2L2’ AND ’Warburg’
’CRC’ AND ’NRF2 OR NFE2L2’ AND ’OXPHOS’.
Fig 1. Simplified diagram of the activation of NRF2 transcription factor via ROS. When ROS is
acumulated, NRF2 is released from Keap1 and heterodimerizes with Small Mafs. In this way, it binds to AREs
and the transcription of antioxidant and cytoprotective genes occurs.
https://doi.org/10.1371/journal.pone.0177549.g001
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We included only scientific reports written in English, and published after 2006, to obtain a
current review of this issue. We collected articles using all combinations of search terms.
Selection process
The articles returned by the searches were manually screened to identify relevant articles to be
included in this review: 1. Search results were integrated using informatics programs. We used
the EndNote reference manager to remove duplicate articles. 2. Titles and abstracts were
assessed to remove irrelevant articles. Only articles satisfying the following criteria were
included: (i) the article considers CRC or other related diseases; (ii) the title of the article
includes the word NRF2, or the name of another related gene; (iii) the article discusses the rela-
tionship between CRC and either mitochondrial biogenesis, OXPHOS or the Warburg effect.
3. The full texts of potentially relevant articles were retrieved and analysed to verify that they
met the inclusion criteria.
Fig 2 shows a flow chart summarising each step in the search process. Reports that did not
meet the inclusion criteria were excluded from the analysis. S1 Table lists the articles excluded
in the last step of the search process.
Assessment of results
Tabulation. We tabulated the following key data from each article: first author, publica-
tion year, organism/cell type, primary results and conclusion (S2 Table).
Heterogeneity. To assess the heterogeneity of the selected articles, we analysed the follow-
ing aspects: expression of NRF2, relationship to CRC, use of cell culture, NRF2 as a chemo-
therapeutic agent, apoptosis, the inflammatory process and mitochondrial function. To more
Fig 2. PRISMA 2009 flow diagram. This flow chart shows the process of selecting articles included in the
qualitative systematic review.
https://doi.org/10.1371/journal.pone.0177549.g002
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easily view the specific characteristics of each article, and to evaluate the homogeneity among
them, we represented each article in a stacked bar chart (Fig 3).
Concept map. We constructed three maps to visualize the links between the selected arti-
cles. We aimed to relate three key concepts behind NRF2 expression and its role in the devel-
opment of CRC so that we could draw conclusions and suggest ideas for future research.
Results
Article selection
The search described above identified relevant articles only in the Pubmed, Web of Science,
and Scopus databases. Removing duplicated articles from these search results resulted in a
total of 104 articles. We reviewed the titles of these articles and discarded those not related to
our topic, reducing the number of articles to 82. We then reviewed the abstracts, further reduc-
ing the number of articles to 60. Finally, we reviewed the full text, and selected 40 articles for
the review. This article selection process is summarized in Fig 2. Articles excluded in the last
step are summarized in Supplementary Information 1.
Tabulation
Complete data from the 40 articles selected for this review are shown in Supplementary Infor-
mation 2. All selected papers were published after 2006. The geographic settings of the studies
vary, with nine from in the USA, nine from China, seven from Korea, four from Germany,
four from Malaysia, three from India, two from Japan, and one each from the United King-
dom, Norway, and Australia. Most studies were based on human cancer cell lines. Only 13
studies used animal experimentation (mice), and four considered patients with ulcerative coli-
tis or Crohn’s disease. The most important results from the selected articles are shown in Sup-
plementary Information 2. Titles, author and publication date of the included articles are
shown in Table 1.
Heterogeneity
The characteristics of each report are shown in Fig 3.
Building a concept map
To interconnect the ideas gathered from the articles included in this review, we constructed
three conceptual maps focused on the expression of NRF2 and its effect on colon cancer. The
Fig 3. Heterogeneity assessment. This graph evaluates if certain features are present in the articles
included in this review.
https://doi.org/10.1371/journal.pone.0177549.g003
Nrf2 and its preventing role in colorectal cancer
PLOS ONE | https://doi.org/10.1371/journal.pone.0177549 May 18, 2017 5 / 14
Table 1. Summarized table about the included reports.
First author Primary results
Kim et al., 2011 [6] Hypoxia-induced angiogenesis can be blocked by inhibiting Nrf2. Inhibition of
Nrf2 reduced tumour growth and decreased angiogenesis in mice xenografts,
and was associated with a lower accumulation of HIF-1 α under hypoxic
conditions. Hypoxia cannot activate HIF-1α in Nrf2-inhibited colon cancer cells.
PGC1-α and NRF1 levels were unaffected by inhibition of Nrf2. However,
destabilization of HIF-1α is associated with a weakened mitochondrial function in
colon cancer cells.
Bat-Chen et al., 2010
[11]




Nrf2 is activated by luteolin
Kim et al., 2013 [13] Catechol residues are essential for activating Nrf2.
Pandurangan et al.,
2015 [14]
Cocoa actives Nrf2 expression.
Li et al., 2016 [15] Nrf2 is activated by luteolin.
Chiou et al., 2011 [16] PS and RS promote Nrf2 activation and reduce colon tumorigenesis.
Trivedi et al., 2013 [17] Lipoic acid (LA) increases Nrf2 and HO-1 expression in the colon. LA protects
against DNA damage in the colon.
Pettersen et al.,2016[18] In SW620 cells, DHA induces an increase in ROS and causes the nuclear import
of Nrf2. An increase in the level of Nrf2 was detected in the nucleus of CaCo2
and SW620 cells.
Myers et al., 2014[19] Nrf2 levels are lower in inflamed tissue of patients with UC and Crohn´s disease.
Nrf2 protein levels were twice as high in patients with diverticulitis than in
patients with UC-associated cancer.
Xi et al., 2013 [20] Nrf2 has an inhibitory effect on the development of the CRC. Nrf2 diminishes the
development of dysplasia. Nrf2 is overexpressed in tumour tissues.
Park et al., 2010 [21] Rottlerin induces Nrf2 nuclear translocation.
Jang et al., 2016 [22] Simvastatin induces Nrf2 expression and its nuclear translocation. Simvastatin
induces Nrf2-related antioxidant expression through the ERK and PI3K/Akt
pathways.
Trivedi et al., 2016 [23] MEL increases the expression of Nrf2 and other target genes.
Xu et al., 2015[24] PYDDT promotes ROS production, increases Nrf2 expression and decreases
the CRC risk due to a reduction in genotoxicity and an increment of apoptosis.
Tan et al., 2015 [25] Brewer’s rice promotes Nrf2 activation.
Volonte et al., 2013 [26] Calveolin inhibits Nrf2 translocation to the nucleus, thereby promoting premature
senescence of CRC cells.
Kruse et al., 2016 [27] IMC-co-cultured NCM460 or Colo320 cancer cells were less sensitive to TRAIL/
etoposide-induced apoptosis due to Nrf2-induced proteasome activity.
Immunostaining of IBD tissues confirmed Nrf2 activation within inflamed areas of
the colonic epithelium, and greater proteasome protein expression.
Yang et al., 2014[28] Low concentrations of digitoflavonoids are potential Nrf2/Are activators in colon
tumour, liver and kidney cells. Digitoflavonoids stimulate the expression of
antioxidant defence proteins, the expression of Nrf2, and its translocation to the
nucleus. After treatment with digitoflavonoids, AKT, ERK1/2 and p38 AMPK
phosphorylation increases. Inhibition of AKT and ERK1/2 phosphorylation does
not influence Nrf2 activation. p38 phosphorylation however is essential for Nrf2
activation. Mice treated with digitoflavonoids exhibited a decrease in the number




Nrf2 transactivation and translocation.
Wondrak et al., 2010
[30]
Cinnamaldehyde upregulates Nrf2 and its downstream target genes. Nrf2
provides protection against oxidative stress-induced genotoxicity.
Li et al., 2009 [31] Exposing HTC116 cells to NO results in the nuclear translocation of Nrf2 as well
as its transcriptional upregulation.
(Continued )
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first conceptual map was constructed on the basis of standard NRF2 gene expression and how
it is influenced by various mechanisms or external agents. The second conceptual map
explains the various effects and mechanisms of NRF2 overexpression, and the third shows the
effects of NRF2 silencing or inhibition. Analysing all three conceptual maps sheds light onto
how NRF2 expression affects CRC. As shown in Fig 4, correct expression of NRF2 prevent
Table 1. (Continued)
First author Primary results
Jung et al., 2013 [32] Silenced Keap1 activates Nrf2 signalling in colon cancer cell lines. Silencing
Keap1 can upregulate the expression of AKRs and attenuate oxidative damage
caused by stress.
Lu et al., 2016 [33] CPUY192018 provides cytoprotection against oxidative damage caused by DSS
in NCM460 cells. Pretreatment with CPUY192018 increases the survival rate by
inhibiting apoptosis and by impeding the DSS-induced arrest of the S phase of
the cell cycle. CPUY192018 induces an increase in Nrf2 protein levels in colonic
NCM460 cells and its accumulation in the nucleus.
Stachel et al., 2014 [34] IER3 overexpression inhibits Nrf2 activation. The absence of IER3 causes a
reduction in ROS levels as a result of an increase in Nrf2 activity.
Sebens et al., 2011 [35] Nrf2 is activated when cells are exposed to inflammatory macrophages. This
increases proteosomal activity and the expression of proteosomal genes in a
Nrf2-dependent manner.
Yokoo et al., 2016[36] In Nrf2-/- mice treated with KBrO3, atypical hyperplasia, adenoma and
adenocarcinoma were all observed in the upper small intestine. These same
mice displayed an increase in the number of aberrant crypts compared with their
Nrf2+/+ counterpart.
Kang et al., 2014 [37] Nrf2 promotes resistance to 5-FU treatment in CRC cells.
Zhao et al., 2015 [38] Nrf2 expression is higher in CRC cells that are resistant to 5-FU treatment.
Hu et al., 2013 [39] Nrf2 is higher expressed in tumour tissue than in normal tissue. Nrf2
overexpression is related to larger tumours with advanced stage and metastasis.
Directional metastases may be associated with activation of Nrf2.
Ji et al., 2014 [40] Nrf2 expression is higher in CRC tissue, and is positively correlated with Duke’s
stage and clinical prognosis.
Kang et al., 2016 [41] Nrf2 expression is higher in those colon cells resistant to 5-FU. Demethylation
upregulates Nrf2 in 5-FU resistant SNUC5 cells.
Ishaq et al., 2014[42] Nrf2 is involved in the protective response of HT29 cancer cells. It induces
apoptosis through activating caspase 3/7.
Arlt et al., 2009 [43] There is a high activity of Nrf2 in the nucleus of CRC cells. Nrf2 overexpression
increases proteasomal activity.
Li et al., 2008 [44] Compared with WT mice, Nrf2 KO mice suffer from more severe ulcerative
colitis, loss of crypts, an infiltration of inflammatory cells, and rectal bleeding.
Khor et al., 2006 [45] Compared with WT mice, Nrf2 KO mice had a smaller average colon length.
After exposure to DSS, Nrf2 KO mice showed a loss in crypts with severe
inflammation.
Osburn et al., 2007 [46] DSS exposure in Nrf2-deficient mice led to the formation of multiple aberrant
crypts. In addition, treatment with AOM promoted colitis-associated
tumorigenesis (due to inflammation of the colon).
Saw et al., 2011 [47] Nrf2 KO mice suffer more severe colitis than WT mice after treatment with DSS.
After adding AOM, Nrf2 KO mice have a greater tendency to develop CRC and
dysplasia, and display increased prolapse and rectal bleeding. Nrf2 is required
for protection against inflammation-associated CRC. Nrf2 KO mice have a
greater susceptibility of developing aberrant crypts associated with
inflammation.
Cheung et al., 2014 [48] Nrf2 KO mice have an increased number and size of polyps and cell
proliferation.
Chang et al., 2013 [49] Proteins of the Nrf2 pathway are actively expressed in CRC.
https://doi.org/10.1371/journal.pone.0177549.t001
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CRC in humans, while altered expression of this gene promotes tumour genesis and progres-
sion (Figs 5 and 6).
Discussion
The articles selected show that research on the role of NRF2 in CRC can be classified into
three broad groups: i) those that analyse standard expression and observe a cytoprotective
effect on CRC [11–17], and those that analyse variations in expression, either ii) overexpres-
sion or iii) inhibition, both leading to increased CRC risk. Below, we discuss the findings in
each of these three lines of research.
The first concept map (Fig 4) shows the protective effect of induced expression of the NRF2
gene on CRC following a moderate accumulation of ROS due to specific external agents [18–
22]. When NRF2 activates, it exerts a cytoprotective effect by decreasing genotoxic damage
and promoting autophagy [23]. Sometimes, NRF2 expression leads to reduced cell
Fig 4. Standard expression of NRF2 and the relation with CRC. Oxidizing agents, the silencing of the
Keap1 or the digitoflavonoids induce the expression of NRF2, decreasing the risk of CRC.
https://doi.org/10.1371/journal.pone.0177549.g004
Fig 5. Overexpression of NRF2 and the relation with CRC. Constitutive activation of NRF2 promotes a
serie of events that lead to an increased risk of CRC.
https://doi.org/10.1371/journal.pone.0177549.g005
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proliferation and increased apoptosis of colon cancer cells [24–27]. In all cases, the authors
observed the same final result, namely reduced risk of CRC. Another example of this behav-
iour was reported by Yang et al. (2014), in which digitoflavonoids were found to act upon p38
and to induce NRF2 target genes and antioxidants. They reported a reduction in both the
number and size of tumours, as well as a decrease in the number of aberrant crypts, further
pointing to a protective effect of NRF2 on CRC [28]. Therefore, expression of NRF2 and its
target genes, such as glutathione synthase, likely play a crucial role in cytoprotective mecha-
nisms against CRC [29–31].
In the studies mentioned up to this point, NRF2 expression is directly induced by the exter-
nal agents. However, NRF2 expression can also be promoted indirectly by other mechanisms,
via the repressor Keap1. For example, Jung and Kwak, 2013 silenced Keap1 and found that
induction of NRF2 promoted the expression of AKR members, which are involved in the
detoxification process, leading to reduced risk of CRC [32]. In another study, Lu et al., 2016
used an inhibitor of its interaction with NRF2, CPUY192018, and observed that activated
NRF2 acted as a protective factor upon exposure to DSS, decreasing CRC risk [33].
In all of these cases, standard NRF2 expression levels function as a protective factor against
CRC by providing cytoprotection and by activating antioxidant target genes. These results are
corroborated by the review by Pandurangan and Esa, (2014) and Pandurangan et al (2014a,
2014b), who also support the idea that expression of NRF2 decreases the risk of CRC [12, 29,
50].
As shown in the second concept map (Fig 5), several studies have reported that NRF2 over-
expression increases risk of CRC. This overexpression can occur for a number of reasons,
including constitutive mutations in the Keap1 repressor gene or in the NRF2 gene itself. Sta-
chel et al. (2014) found that excessive levels of ROS induced overexpression of NRF2, leading
to inflammation of the colon tissue and promoting tumorigenesis [34]. In another study,
Sebens et al. (2011) reported overexpression of NRF2 in tissues exposed to inflammatory mac-
rophages, and a simultaneous increase in the activity of proteosomal genes, leading to reduced
apoptosis and uncontrolled proliferation. This in turn results in greater risk of CRC [35].
Other authors have observed similar results when NRF2 is overexpressed as a consequence of
silencing, or as a result of epigenetic changes in this gene [36–38, 51]. Another way to induce
overexpression of NRF2 is using chemical compounds. Kim et al. (2011) found that T-BHQ-
induced overexpression of NRF2 resulted in increased O2 consumption, which is correlated
with higher HIF-1α and VEGF signalling, which in turn directly increases angiogenesis and
tumour growth [6]. Therefore, as mentioned above, overexpression of the NRF2 gene is closely
linked to increased risk of CRC [39, 40]. In this case, CRC risk can increase by promoting
colonic inflammation, decreasing apoptosis, or promoting angiogenesis and uncontrolled cell
proliferation.
Fig 6. Inhibition of NRF2 and the relation with CRC. Inhibition or permanently silencing of NRF2 induce the
formation of aberrant crypts and other typical processes related to the increased risk of CRC such as rectal
bleeding or ulcerative colitis.
https://doi.org/10.1371/journal.pone.0177549.g006
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Notably, NRF2 overexpression has also been linked to increased resistance to the chemo-
therapeutic agent 5-FU via the activity of demethylases and methyltransferases. In addition to
the increase risk of CRC, this implies a poorer response to treatments based on this agent.
[37,41].
The third concept map (Fig 6) shows that inhibited expression of NRF2 also has conse-
quences for this type of cancer, since one of NRF2’s functions is to protect against damaging
and carcinogenic substances [42,43]. Various studies highlight the role of NRF2 on CRC via its
inhibition. Li et al. (2008) related Nrf2 inhibition with increased risk of CRC [44]. Yokoo et al.
(2016) found that silencing Nrf2 resulted in decreased expression of the COX2 gene, leading to
an increase in the number of aberrant crypts, resulting in the formation of adenoma, adenocar-
cinoma and ultimately CRC [36]. Other studies have compared the effects of silencing the Nrf2
gene in mice and exposing them to treatments that induce ulcerative colitis (DSS) or colon car-
cinogenesis (AOM) [45–46]. Nrf2 knockout mice with ulcerative colitis suffer prolapse, rectal
bleeding, inflammation, and as in the previous case, show an increase in the number of aberrant
crypts. Together, these symptoms contribute to the development of CRC. This information is
corroborated by reviews from Saw and Kong in 2011 [47] and Cheung et al. in 2014 [48].
Analysing the behaviour of this gene, not at a single time point, but throughout the various
stages, Chang et al. (2013) suggested that the differential expression profile of NRF2 in tumour
versus normal tissue could be an interesting new target for CRC treatment [49]. Similarly, Arlt
et al. (2009) observed that NRF2 expression is beneficial during early stages, but can contribute
to tumorigenesis in the colon at later stages [43]. These data are also supported by Menegon
et al (2016) and Sporn M and Liby K (2012), who described NRF2 not only as an oncogene but
also as a tumour suppressor gene [52,53]. In addition, few studies have analysed the role of Sin-
gle Nucleotide Polymorphisms (SNPs) in this gene and its promotor, although Yokoo et al.
(2016) suggested that some SNP alleles in the NRF2 gene could increase CRC risk based on
previous studies of these polymorphisms and the risk of ulcerative colitis [36].
Finally, another important factor is the type of cell used in the studies included in this
review. Most of the articles focus on colon stem cells, which need more energy and therefore
require greater expression of NRF2 to obtain the necessary ATP for proliferation, migration
and differentiation, such that altered expression of NRF2 increases genetic instability leading
to increased CRC risk. In vivo, these cells migrate to the apical part of the crypt and become
mature epithelial cells, and altered expression of NRF2 during migration and differentiation,
will lead to an accumulation of mutations that promote tumorigenesis due to absence of cyto-
protection. Thus, NRF2 function is probably essential in both the stem cells of the colon and in
mature epithelial cells [54].
Although we searched several databases using an exhaustive list of relevant terms, our study
has some limitations. We only selected articles published in English, which could result in
selection bias. In addition, the use as search terms such as oxidative phosphorylation, mito-
chondria or Warburg effect, could limit the selection of articles that relate NRF2 to colorectal
cancer, although searches performed without these concepts in several databases did not
return any additional relevant articles.
In conclusion, it is clear that the NRF2 transcription factor has a very complex role in the
cell, and that its expression can be strongly affected by external agents. Any disruption of its
standard expression, be it overexpression or silencing, can promote the genesis and progres-
sion of CRC. Further studies are needed to clarify the role of NRF2, particularly to analyse the
role of various SNPs that could generate variability in the expression and function of the pro-
tein in humans, as well as to study the pathways regulated by this gene, and possible interac-
tions with environmental and behavioural factors, although such studies require large sample
sizes.
Nrf2 and its preventing role in colorectal cancer
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tion and glutathione S-transferase P1 expression via ERKs and p38-MAPK pathways and protect
human colonic cells against oxidative stress. Eur J Nutr. 2012; 51: 881–92. https://doi.org/10.1007/
s00394-011-0269-1 PMID: 22042007
10. Popay J, Roberts H, Sowden A, Petticrew M, Arai L, Rodgers M, et al. Guidance on the conduct of nar-
rative synthesis in systematic reviews. A product from the ESRC methods programme Version. 2006;
1, b92.
11. Bat-Chen W, Golan T, Peri I, Ludmer Z, Schwartz B. Allicin purified from fresh garlic cloves induces
apoptosis in colon cancer cells via NRF2. Nutr Cancer. 2010; 62(7):947–57. https://doi.org/10.1080/
01635581.2010.509837 PMID: 20924970
12. Pandurangan AK, Esa NM. Luteolin, a bioflavonoid inhibits colorectal cancer through modulation of mul-
tiple signaling pathways: A review. Asian Pacific J Cancer Prev. 2014; 15(14):5501–8.
13. Kim H, Kim W, Yum S, Hong S, Oh J, Lee J, et al. Free Radical Biology and Medicine Caffeic acid phe-
nethyl ester activation of NRF2 pathway is enhanced under oxidative state : Structural analysis and
potential as a pathologically targeted therapeutic agent in treatment of colonic in fl ammation. Free
Radic Biol Med. 2013; 65:552–62
14. Pandurangan AK, Saadatdoust Z, Hamzah H, Ismail A. Dietary cocoa protects against colitis-associ-
ated cancer by activating the NRF2/Keap1 pathway. BioFactors. 2015; 41(1), 1–14. https://doi.org/10.
1002/biof.1195 PMID: 25545372
15. Li Y, Shen L, Luo H. International Immunopharmacology Luteolin ameliorates dextran sulfate sodium-
induced colitis in mice possibly through activation of the NRF2 signaling pathway. Int Immunopharma-
col. 2016; 40:24–31.
16. Chiou YS, Tsai ML, Nagabhushanam K, Wang YJ, Wu CH, Ho CT, et al. Pterostilbene is more potent
than resveratrol in preventing azoxymethane (AOM)-induced colon tumorigenesis via activation of the
NF-E2-related factor 2 (NRF2)-mediated antioxidant signaling pathway. J. Agric. Food Chem 2011; 59
(6), 2725–33. https://doi.org/10.1021/jf2000103 PMID: 21355597
17. Trivedi PP, Jena GB. Role of a -lipoic acid in dextran sulfate sodium-induced ulcerative colitis in mice :
Studies on inflammation, oxidative stress, DNA damage and fibrosis. FOOD Chem Toxicol. 2013; 59,
339–55. https://doi.org/10.1016/j.fct.2013.06.019 PMID: 23793040
18. Pettersen K, Monsen VT, Hakvåg Pettersen CH, Overland HB, Pettersen G, Samdal H, et al. DHA-
induced stress response in human colon cancer cells—Focus on oxidative stress and autophagy. Free
Radic Biol Med. 2016; 90:158–72. https://doi.org/10.1016/j.freeradbiomed.2015.11.018 PMID:
26585906
19. Myers JN, Schaffer MW, Korolkova OY, Williams AD, Gangula PR, M’Koma AE. Implications of the
colonic deposition of free hemoglobin-alpha chain: a previously unknown tissue by-product in inflamma-
tory bowel disease. 2014; 20(9), 1530–47.
20. Xi M, Sun Z, Sun H, Jiang J, Wang Y, Zhang M. 3-aroylmethylene-2,3,6,7-tetrahydro-1H-pyrazino[2,1-
a]isoquinolin-4(11bH)-ones as potent NRF2/ARE inducers in human cancer cells and AOM-DSS
treated mice. J. Med. Chem. 2013; 56(20), 7925–38 https://doi.org/10.1021/jm400944k PMID:
24053646
21. Park EJ, Lim JH, Nam SI, Park JW, Kwon TK. Rottlerin induces heme oxygenase-1 (HO-1) up-regula-
tion through reactive oxygen species (ROS) dependent and PKC δ-independent pathway in human
colon cancer HT29 cells. Biochimie. 2010; 92(1), 110–15. https://doi.org/10.1016/j.biochi.2009.10.001
PMID: 19833168
22. Jang HJ, Hong EM, Kim M, Kim JH, Jang J, Park SW, et al. Simvastatin induces heme oxygenase-1 via
NF-E2-related factor 2 (NRF2) activation through ERK and PI3K/Akt pathway in colon cancer. Oncotar-
get.2016; 7(29).
23. Trivedi PP, Jena GB, Tikoo KB, Kumar V. Melatonin Modulated Autophagy and NRF2 Signaling Path-
ways in Mice With Colitis-Associated Colon Carcinogenesis. Mol Carcinog. 2016 Mar; 55(3):255–67.
https://doi.org/10.1002/mc.22274 PMID: 25598500
Nrf2 and its preventing role in colorectal cancer
PLOS ONE | https://doi.org/10.1371/journal.pone.0177549 May 18, 2017 12 / 14
24. Xu DG, Lv W, Dai CY, Zhu FF, Xu GH, Ma ZJ, et al. 2-(Pro-1-ynyl)-5-(5,6-dihydroxypenta-1,3-diynyl)
thiophene induces apoptosis through reactive oxygen species-mediated JNK activation in human colon
cancer SW620 cells. Anat Rec. 2015; 298(2):376–85.
25. Tan BL, Norhaizan ME, Huynh K, Yeap SK, Hazilawati H, Roselina K. Brewers ‘ rice modulates oxida-
tive stress in azoxymethane- mediated colon carcinogenesis in rats. 2015; 21(29):8826–35.
26. Volonte D, Liu Z, Musille PM, Stoppani E, Wakabayashi N. Inhibition of nuclear factor-erythroid 2 –
related factor (NRF2) by caveolin-1 promotes stress- induced premature senescence. Mol Bio Cell.
2013; 24(12), 1852–62.
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